Toboroz
SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
NCT07855900· 3. fázis· Boehringer Ingelheim· Forrás
Még nem toboroz
Low-Dose Radiotherapy for Painful Knee Osteoarthritis
NCT07886697· Universidad Rey Juan Carlos· Forrás
Toboroz
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
NCT07770841· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
Grass/Olive Immunotherapy for Rhinitis and Asthma (GOES)
2025-521709-42-00· 3. fázis· LETI Pharma S.L.U.· Forrás
Toboroz
Grass Immunotherapy for Rhinitis and Asthma (GIRA)
2025-521736-10-00· 3. fázis· LETI Pharma S.L.U.· Forrás
Toboroz
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study
2025-522338-30-00· 2. fázis· Eli Lilly & Co.· Forrás
Még nem toboroz
Phase 1b/2 Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination with Carboplatin, Pemetrexed and Tislelizumab in Patients with Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer
2025-521989-95-00· 1/2. fázis· Oncomatryx Biopharma S.L.· Forrás
Toboroz
Inhaled Sedation in Critically Ill Patients
NCT07000526· 4. fázis· Instituto de Investigación Hospital Universitario La Paz· Forrás
Toboroz
External Validation of the CLOVER Score for Detecting Occult Cancer in Venous Thromboembolism Patients
NCT07310693· Infanta Leonor University Hospital· Forrás
Toboroz
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101· 2. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
NCT06456593· 2. fázis· Abivax S.A.· Forrás
Toboroz
Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)
NCT06684379· 1/2. fázis· PEACHES BIOTECH· Forrás
Fut, nem toboroz
EFFICACY AND SAFETY OF CROMOGLYCATE AS A NEW SYMPTOMATIC TREATMENT IN PATIENTS WITH MULTIPLE SCLEROSIS
2023-507541-29-00· 2. fázis· Fundacion Para La Investigacion Biomedica Del Hospital Clinico San Carlos· Forrás
Toboroz
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542· 2. fázis· AbbVie· Forrás
Fut, nem toboroz
POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol After Gastric Surgery (POWER 4 + 3)
NCT06790238· Grupo Español de Rehabilitación Multimodal· Forrás
Toboroz
CRS Questionnaire Validation Project
NCT06970977· The European Forum for Research and Education in Allergy and Airway Diseases· Forrás
Toboroz
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
NCT06311682· 3. fázis· LEO Pharma· Forrás
Fut, nem toboroz
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738· 3. fázis· Olema Pharmaceuticals, Inc.· Forrás
Fut, nem toboroz
A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain
NCT06125795· AbbVie· Forrás
Toboroz
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma
NCT05466799· 2. fázis· OncoSil Medical Limited· Forrás
Toboroz
Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624
NCT05781217· 3. fázis· Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic· Forrás
Toboroz
High Definition Medicine for Solid Tumors Oncology
NCT06590506· Centro Nacional de Investigaciones Oncologicas CARLOS III· Forrás
Fut, nem toboroz
ABTECT - Maintenance
NCT05535946· 3. fázis· Abivax S.A.· Forrás
Toboroz
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654· 3. fázis· Gilead Sciences· Forrás
Toboroz
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
NCT05558319· 3. fázis· PETHEMA Foundation· Forrás
Fut, nem toboroz
Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT
2024-517008-12-00· 3. fázis· Fundacion PETHEMA· Forrás
Toboroz
OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.
NCT04493632· OncoSil Medical Limited· Forrás
Toboroz
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846· 3. fázis· AbbVie· Forrás
Toboroz
Clinical Trial on HIPEC With Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)
NCT05250648· 4. fázis· Hospital Universitario de Fuenlabrada· Forrás
Fut, nem toboroz
Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer
NCT04759248· 2. fázis· SOLTI Breast Cancer Research Group· Forrás
Fut, nem toboroz
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
NCT04595565· 3. fázis· GBG Forschungs GmbH· Forrás
Fut, nem toboroz
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
NCT04524611· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
NCT03937154· 3. fázis· Amgen· Forrás
Fut, nem toboroz
Clinical trial to compare the efficacy of two treatment sequencing schemes with chemotherapy (the regime called FOLFOX and FOLFIRI) in combination with biologic drugs (panitumumab and bevacizumab).
NCT03635021· 3. fázis· Asociacion Grupo Tratamiento De Tumores Digestivos· Forrás
Fut, nem toboroz
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
NCT02947685· 3. fázis· Alliance Foundation Trials, LLC.· Forrás
Toboroz
A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)
NCT02819882· Spanish Breast Cancer Research Group· Forrás
Toboroz
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
NCT02832245· Manuel Monreal· Forrás